1. Home >
  2. Revvity Acquires Oxford Immunotec Global

M&A Deal Summary

Revvity Acquires Oxford Immunotec Global

On January 7, 2021, Revvity acquired medical products company Oxford Immunotec Global for 591M USD

Acquisition Highlights
  • This is Revvity’s 9th transaction in the Medical Products sector.
  • This is Revvity’s 4th largest (disclosed) transaction.
  • This is Revvity’s 2nd transaction in the United Kingdom.

M&A Deal Summary
Date 2021-01-07
Target Oxford Immunotec Global
Sector Medical Products
Buyer(s) Revvity
Deal Type Add-on Acquisition
Deal Value 591M USD
Advisor(s) Perella Weinberg Partners (Financial)
Covington & Burling (Legal)

Target

Oxford Immunotec Global

Abingdon, United Kingdom
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company’s first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company’s second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. Oxford Immunotec Global was founded in 2002 and is based in Abingdon, the United Kingdom.

Search 204,782 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Revvity

Waltham, Massachusetts, United States
Category Company
Founded 1937
Sector Medical Products
Employees11,000
Revenue 2.8B USD (2023)
DESCRIPTION

Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Revvity was formerly known as PerkinElmer. The Company was formed in 1937 and is based in Waltham, Massachusetts.

DEAL STATS #
Overall 32 of 36
Sector (Medical Products) 9 of 11
Type (Add-on Acquisition) 30 of 34
Country (United Kingdom) 2 of 3
Year (2021) 1 of 5
Size (of disclosed) 4 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-11-02 Horizon Discovery Group

Cambridge, United Kingdom

Horizon Discovery Group PLC is an international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines. Horizon Discovery Group was founded in 2007 and is based in Cambridge, the United Kingdom.

Buy £296M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-12 Nexcelom Bioscience

Lawrence, Massachusetts, United States

Nexcelom Bioscience is a designer, manufacturer, and marketer of innovative Cellometer and Celigo image cytometry products designed for cell analysis in life science and biomedical research. Nexcelom Bioscience was founded in 2003 and is based in Lawrence, Massachusetts.

Buy $260M
Mergr

Product

Company

Legal